About
Technology
Issues
FAQ
Links
Official Page
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.